Search published articles

Showing 8 results for Haghollahi

Farnaz Sohrabvand, Fedyeh Haghollahi, Masoomeh Maasomi, Leila Asgarpoor, Mamak Shariat, Mahtab Hamedani,
Volume 7, Issue 4 (7-2009)

Background: In spite of the great progress in assisted reproductive techniques ( ART), and although good quality embryos are transferred,  pregnancy rates have remained around 30%-35% due to low implantation rates.
Objective: The aim of this study was to assess and compare the effects of administrating indomethacin or hyoscine suppositories prior to embryo transfer on the pregnancy rate in ART cycles.
Materials and Methods: This double-blind clinical trial was performed in Vali-e-Asr Hospital as a pilot study from August 2005 through December 2006 on 66 infertile women in ART cycles. Controlled ovarian hyperstimulation  was done using recombinant FSH (Gonal-F) with a long GnRH analogue protocol. After obtaining written consent, the subjects were randomly allocated into three  equal groups (n=22). Groups A and B received  indomethacin and hyoscine rectal suppositories, respectively 30 minutes  before embryo transfer and group C was the control group. Data were analyzed by χ2 , t-test, ANOVA, and Kruskall Wallis tests.
Results: Overall pregnancy rate was 31% (n=21) with 13.6% (n=3) in  group A,  45.5% (n=10), and 36% (n=8) in groups B and C respectively, which shows that pregnancy rate is significantly higher in the group using hyoscine compared to  the other two groups (p=0.04). Uterine muscle cramps were experienced by 3 women (13.6%) in group C while none were reported by women in groups A or B, which shows a significant difference (p<0.04).
Conclusion: It seems that  compared to indomethacin, hyoscine administration 30 minutes prior to embryo transfer can significantly increase pregnancy rates  by reducing uterine and cervical muscle spasm.
Ensieh Tehraninejad, Akram Ghahghaei Nezamabadi, Batool Rashidi, Maryam Sohrabi, Maryam Bagheri, Fedyeh Haghollahi,
Volume 9, Issue 3 (7-2011)

Background: General concern is that the pregnancy rate is higher with GnRH-agonist as a protocol of pituitary suppression. GnRH-antagonist protocol provides a shorter period of administration and an easy flexible protocol.
Objective: In this study, the outcomes of GnRH agonist and antagonist in ICSI cycles are compared in normo responder patients.
Materials and Methods: In this randomized clinical trial, 300 normoresponders undergoing ICSI were randomly divided to GnRh agonist (n=150) and GnRh antagonist (n=150) groups. The main outcome measurements were chemical, clinical and ongoing pregnancy rates (PR).
Results: The mean duration of stimulation were 9.6±1.6 and 8.2±1.6 days in agonist and antagonist groups respectively (p=0.001). The mean number of MII oocyte retrieved in agonist and antagonist groups were 7.7±4.0 and 6.9±4.3 respectively (p=0.03). There was no significant difference between two groups regarding mean number of gonadotrophin ampoules, follicles, occytes, total embryos and good quality embryos, OHSS incidence, and abortion rate. Chemical pregnancy rate was 35.3% in agonist and 39.3% in antagonist group. Clinical pregnancy rate was 35.3% in agonist and 34% in antagonist group. Ongoing pregnancy rate was 45 (31.3%) in agonist and 44 (29.3%) in antagonist group. There was no significant difference between two groups in pregnancy rates.
Conclusion: In this study antagonist protocol was shown to be an easy, safe and friendly protocol in Iranian normoresponder patients, having similar outcomes with standard agonist protocol but shorter period of stimulation.
Farnaz Sohrabvand, Shahrzad Sheikhhassani, Maryam Bagheri, Fedyeh Haghollahi, Maryam Shabihkhani, Mamak Shariat, Manijeh Nasr Esfahani,
Volume 10, Issue 3 (7-2012)

Background: Polycystic ovary syndrome (PCOS) is a common cause of ovulatory disorders and infertility with high LH to FSH ratio. In order to prevent further increase of LH and follicle atresia, different regimens for ovulation induction have been recommended using FSH alone.  
Objective: This study was performed in PCOS patients to compare ART outcomes in cycles induced by FSH alone, using either recombinant or urinary products.  
Materials and Methods: In a randomized trial, from 623 patients who underwent down regulation with GnRH analogue in a long protocol, 160 PCOS patients were randomly divided into two groups of 80. Group A received 150 IU/d recombinant FSH (Gonal-F) and group B 150 IU/d urinary FSH (Fostimon).
Results: 33 cases (41.2%) in group A and 36 (45%) in group B achieved clinical pregnancy, which was not significantly different (p=0.67). Total number of oocytes retrieved (13.03±5.56 vs. 14.17±4.89, p=0.17), quality and number of embryos (7.42±3.35 vs. 7.63±3.28, p=0.68) and OHSS rate were similar in group A compared to group B. Endometrial thickness which was 9.66±1.67 mm in group A and 10.36±1.35 mm in group B, showed a significant difference (p=0.004).
Conclusion: It seems that in PCOS patients, both pure FSH products used for controlled ovarian hyperstimulation have similar effects on ART outcome and can be used according to availability and patient acceptance without significant difference.
Tahereh Eftekhar, Maryam Sohrabi, Fedyeh Haghollahi, Mamak Shariat, Elahe Miri,
Volume 12, Issue 1 (2-2014)

Background: Female sexual dysfunction is a common problem among general population, especially in urogynecological patient, and can lead to a decrease in quality of life and affect martial relationship.
Objective: This study was compared the effect of surgical methods versus physiotherapy on sexual function in pelvic floor disorder.
Materials and Methods: This randomized controlled trial (RCT) was performed in Urogynecology clinic since August 2007 to December 2009 on 90 patients aged from 25-55 years with previous delivery, positive history of sexual dysfunction with stage <3 of pelvic organ prolapsed and divided in two groups. Group A (n=45) received standard rectocele repair and prineorrhaphy, group B (n=45) received physiotherapy for eight weeks twice a week (electrical stimulation, Kegel exercises). The female sexual function index (FSFI) used to evaluate the sexual function in cases before and after intervention. Frequency of variable scores (libido, orgasm, dysparunia) included without disorder, frequently good, sometimes good, very much and extreme were compared between two groups.
Results: Libido and arousal were improved in both groups (p=0.007, p=0.001 respectively). Orgasm and dyspareunia were improved in group B (p=0.001). Dysparunia was more painful in group A. There was significant difference between two groups (improvement of orgasm and dysparunia in group B) (p=0.001).
Conclusion: It seems that physiotherapy is an appropriate method for treatment of sexual disorder in pelvic floor disorder.
Tahereh Eftekhar, Farnaz Sohrabvand, Neda Zabandan, Mamak Shariat, Fedyeh Haghollahi, Akram Ghahghaei-Nezamabadi,
Volume 12, Issue 8 (8-2014)

Background: Polycystic Ovary Syndrome (PCOS) is presented with characteristic complications such as chronic an ovulation, obesity, and hyperandrogenism which can affect sexual function in women of reproductive age.
Objective: Herein we evaluated the frequency and predisposing factors of sexual dysfunction in infertile PCOS patients.
Materials and Methods: In this cross-sectional study, 130 married women with a definite diagnosis of PCOS who were referred due to infertility were recruited. They were evaluated concerning their sexual function in the domains of desire, arousal, lubrication, orgasm, satisfaction and pain with the female sexual function index (FSFI) questionnaire.
Results: The frequency of sexual dysfunction was verified 57.7% in PCOS patients with the domains of desire and arousal being commonly affected in 99.2% and 98.5%of cases respectively. BMI had a significant effect on sexual desire and arousal (p=0.02) while the effect of hirsutism was significant on all domains (p<0.001 for total FSFI score) except for dyspareunia.
Conclusion: PCOS patients markedly suffer from sexual dysfunction as comorbidity. It seems appropriate to screen all PCOS patients for sexual function with a simple short questionnaire such as FSFI. Targeted interventions could be considered to help improve their quality of life along with other treatments. 
Ensieh Shahrokh Tehraninejad, Mina Farshbaf Taghinejad, Batool Hossein Rashidi, Fedyeh Haghollahi,
Volume 15, Issue 7 (8-2017)

Background: Different combination of gonadotropin preparation has been introduced with no definite superiority of one over others in in vitro fertilization (IVF), but individualized regimens for each patient are needed.
Objective: The aim of the present study was to investigate the effect of controlled ovarian stimulation with recombinant- follicle stimulating hormone (r-FSH) plus recombinant-luteinizing hormone (rLH) versus human menopausal gonadotropin (HMG) plus r-FSH on fertility outcomes in IVF patients.
Materials and Methods: This is a randomized clinical trial study that was performed from October 2014-April 2016 on 140 infertile patients with a set of inclusion criteria that referred to infertility clinics in Vali- asr and Gandhi Hospital in Tehran. The women were randomly divided into two treatment groups. The first group (n=70) received rFSH from the second day of cycle and was added HMG in 6th day and the 2nd group (n=70), received rFSH from the second day of cycle and was added recombinant-LH in 6th day. Then ovum Pick-Up and embryo transfer were performed. In this study, we assessed the outcomes such as; chemical and clinical pregnancy rate, live birth and abortion rate.
Results: Number of follicles in ovaries, total number of oocytes or M2 oocytes and quality of fetuses has no significant differences between two groups (p>0.05). Total number of fetuses were significantly higher in patients who received rFSH + HMG (p=0.02). Fertility outcomes consisted of: live birth rate, chemical pregnancy and clinical pregnancy rate were higher in rFSH + HMG group in comparison to rFSH +r-LH group (p<0.05).
Conclusion: It seems that in IVF patients, HMG + rFSH used for controlled ovarian hyperstimulation have better effects on fertility outcomes, but in order to verify the results, it is recommended to implement studies on more patients.
Ensieh Shahrokh Tehrani Nejad , Fatemeh Bakhtiari Ghaleh, Bita Eslami, Fedyeh Haghollahi, Maryam Bagheri, Masoumeh Masoumi,
Volume 16, Issue 8 (August 2018)

Background: Both oral contraceptive pills (OCPs) and estradiol valerate (E2) have been used to schedule a gonadotropin-releasing hormone antagonist in vitro fertilization (IVF) cycles. Since the suppression of follicle-stimulating hormone by OCPs can stay 5-7 days after stopping the pills, it seems that starting the gonadotropin-releasing hormone (GnRH) after 6 days of pre-treatment discontinuation may be important in IVF outcomes.
Objective: The aim of the present study was to determine the number of mature oocyte and pregnancy rate of three pretreatment methods for fresh embryo transfer cycles.
Materials and Methods: In this randomized controlled trial, two-hundred ten women (18-35 yr and less than 2 previous IVF attempts) undergoing IVF with the GnRH antagonist protocol were randomized to the OCP, E2, and no pretreatment arms. OCP group (n=53) received OCP (ethinyl estradiol30 μg and levonorgestrel150 μg), E2 group (n=63) received 4 mg/day oral E2 (17β‐E2) for 10 days from day 20 of the previous cycle and GnRH antagonist stimulation was started 6 days after the interruption of OCP and E2. The control group (n =70) did not receive any pretreatment.
Results: No significant difference was observed in the mean number of the mature oocyte, endometrial thickness, and embryo quality. The pregnancy rate in E2 group was higher than the two other groups (42.9% vs 39.6% and 34.3% in OCP and control group, respectively), but the difference was not statistically significant (p=0.59).
Conclusion: It seems OCP or E2 pretreatment could not improve the fresh IVF-embryo transfer outcomes
Masoumeh Hajshafiha, Tahere Behrouzi Lak, Nasrin Hajiloo, Yaghoub Deldar, Mina Ghorbani, Fedyeh Haghollahi,
Volume 16, Issue 12 (December 2018)

Background: The failure to retrieve oocytes from mature ovarian follicles is referred to as empty follicle syndrome. There is no exact explanation to this problem and it cannot be predicted using ultrasound or serum hormonal levels. The underlying mechanism of
Empty follicle syndrome remains obscure.
Objective: In this study, the authors have investigated the relationship between the Beta-Human chorionic gonadotropin (𝛽HCG) levels in the follicular fluid with or without the oocyte in the follicles of patients undergoing Intracytoplasmic Sperm Injection.
Materials and Methods: Seventy-three infertile couples underwent standard long protocol induction ovulation for Intracytoplasmic sperm injection. On the day of oocyte retrieval, each patient had two samples; follicular fluid including 2–3 follicles with oocyte and follicular fluid including of 2–3 follicles without oocyte were collected in separate tubes. These follicles had similar shape and size. The Samples were transferred to a laboratory for measuring the 𝛽HCG level, after which the 𝛽HCG levels were compared to the follicles with and without the oocyte in each patient.
Results: In this study, the 𝛽HCG level of follicular fluid in the follicles containing oocyte was 18.20 (8.35–42.92) IU/L and in the follicles without the oocyte was 13.50 (5.45– 25.81) IU/L. Levels of 𝛽HCG in the follicular fluids containing the oocyte were higher than without oocytes, This difference was not statistically significant (p = 0.16).
Conclusion: It seems that the follicular fluid 𝛽HCG isn’t caused by empty follicle syndrome, and that dysfunctional folliculogenesis may be the cause of this syndrome.


Page 1 from 1     

© 2021 CC BY-NC 4.0 | International Journal of Reproductive BioMedicine

Designed & Developed by : Yektaweb